Exelixis Announces FDA Approval of CABOMETYX for thyroid cancer

 – FDA approval based on phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in progression-free survival with CABOMETYX versus placebo –

– Exelixis is prepared to fully support expanded indication immediately –

– Application approved well ahead of Prescription Drug User Fee Act target action date of December 4, 2021 –

https://www.biospace.com/article/releases/exelixis-announces-u-s-fda-approval-of-cabometyx-cabozantinib-for-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer/